GS
LYEL icon

GTS Securities’s Lyell Immunopharma LYEL Stock Holding History

GTS Securities’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-652
Closed -$7.02K – 1463
2025
Q1 		$7.02K Buy
+652
New +$7.99K ﹤0.01% 1206
2023
Q4 		– Sell
-755
Closed -$22.2K – 4253
2023
Q3 		$22.2K Buy
+755
New +$35.9K ﹤0.01% 3790

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

GTS Securities's LYEL Position: Q2 2025 in Review

GTS Securities sold out of Lyell Immunopharma (LYEL) in Q2 2025, closing a stake of 652 shares — an estimated $7.02K sold.

GTS Securities first reported a position in LYEL in Q3 2023 and held it in 2 quarters. The position peaked at $22.2K in Q3 2023. 69 funds tracked by Wall St. Rank hold LYEL as of Q2 2025.

  • GTS Securities reported no remaining Lyell Immunopharma position as of Q2 2025 after selling out during the quarter.
  • GTS Securities sold 652 Lyell Immunopharma shares in Q2 2025, an estimated $7.02K.
  • GTS Securities first reported a position in Lyell Immunopharma in Q3 2023 and held it in 2 quarters.
  • GTS Securities's Lyell Immunopharma position peaked at $22.2K in Q3 2023.
  • 69 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2025.

Based on GTS Securities's 13F filing for Q2 2025, filed 8 Aug 2025.